Sun’s Ilumya Gnaws At US Psoriasis Market

Around 800 physicians have prescribed Sun’s Ilumya, giving it some early traction in the competitive US psoriasis market. The Indian firm is striving to push harder and will also take a call on pursuing additional indications for the product.

Psoriasis
SUN'S ILUMYA HAS MADE INROADS INTO THE PSORIASIS MARKET

Sun Pharmaceutical Industries Ltd.’s psoriasis asset, Ilumya (tildrakizumab), has made inroads into the US psoriasis market, garnering early attention from some physicians despite being up against formidable competition.

Ilumya has been well received, with close to 800 physicians having prescribed the product to date, Sun says. The Indian...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip